Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
February 27, 2015 09:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
February 04, 2015 09:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
January 21, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases...
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
January 12, 2015 12:32 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
January 12, 2015 09:26 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
December 02, 2014 07:45 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
November 18, 2014 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
November 18, 2014 07:45 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
November 12, 2014 08:30 ET
|
Capricor Therapeutics, Inc.
Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy
Conference Call Scheduled for Wednesday, November 12, 2014 (4:30 p.m. EST)
LOS ANGELES,...
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
November 07, 2014 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...